佐力药业
(300181)
| 流通市值：78.02亿 | | | 总市值：90.83亿 |
| 流通股本：6.02亿 | | | 总股本：7.01亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,764,138,447 | 897,797,296.94 | 3,040,763,497.87 | 2,279,713,382.85 |
| 营业收入 | 1,764,138,447 | 897,797,296.94 | 3,040,763,497.87 | 2,279,713,382.85 |
| 二、营业总成本 | 1,352,533,232.92 | 674,900,714.95 | 2,370,426,574.04 | 1,720,477,214.14 |
| 营业成本 | 659,352,593.85 | 324,692,212.6 | 1,167,641,885.34 | 865,634,716.16 |
| 税金及附加 | 19,767,545.91 | 6,948,543.06 | 33,094,051.82 | 22,027,818.71 |
| 销售费用 | 582,331,319.16 | 293,073,843.91 | 961,455,041.94 | 706,537,994.76 |
| 管理费用 | 60,944,998.72 | 36,040,543.39 | 128,982,642.17 | 77,841,865.65 |
| 研发费用 | 22,647,736.3 | 10,615,785.97 | 69,419,299.59 | 41,831,115.46 |
| 财务费用 | 7,489,038.98 | 3,529,786.02 | 9,833,653.18 | 6,603,703.4 |
| 其中:利息费用 | 8,614,569.7 | 4,133,061.12 | 14,441,280.72 | 10,619,729.55 |
| 其中:利息收入 | 1,200,790.66 | 640,442 | 4,780,637.12 | 4,147,479.09 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -1,261,638.56 | -828,675.78 | -3,459,900.01 | -2,184,112.19 |
| 资产处置收益 | -172,620.84 | 2,132.45 | 591,239.16 | 33,840.38 |
| 资产减值损失(新) | -4,895,364.81 | -2,243,762.31 | -10,614,745.63 | -3,272,832.21 |
| 信用减值损失(新) | -6,375,460.66 | -6,473,901.17 | -6,741,001.76 | -10,277,114.58 |
| 其他收益 | 48,389,719.91 | 24,644,547.89 | 116,817,313.29 | 74,205,638.39 |
| 四、营业利润 | 447,289,849.12 | 237,996,923.07 | 766,929,828.88 | 617,741,588.5 |
| 加:营业外收入 | 196,257.92 | 72,929.96 | 249,420.31 | 136,995.52 |
| 减:营业外支出 | 814,819.48 | 462,613.33 | 11,511,364.53 | 7,118,333.72 |
| 五、利润总额 | 446,671,287.56 | 237,607,239.7 | 755,667,884.66 | 610,760,250.3 |
| 减:所得税费用 | 67,408,492.38 | 35,595,617.95 | 113,231,231.86 | 92,648,589.48 |
| 六、净利润 | 379,262,795.18 | 202,011,621.75 | 642,436,652.8 | 518,111,660.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 379,262,795.18 | 202,011,621.75 | 642,436,652.8 | 518,111,660.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 374,928,879.39 | 199,592,681 | 631,933,709 | 509,974,478.8 |
| 少数股东损益 | 4,333,915.79 | 2,418,940.75 | 10,502,943.8 | 8,137,182.02 |
| 扣除非经常损益后的净利润 | 373,641,775.49 | 198,698,412.53 | 617,361,420.2 | 508,517,732.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.55 | 0.28 | 0.92 | 0.73 |
| (二)稀释每股收益 | 0.53 | 0.28 | 0.91 | 0.73 |
| 八、其他综合收益 | -21,869,814.39 | 38,704,464.72 | 104,850,057.77 | 193,161,979.42 |
| 归属于母公司股东的其他综合收益 | -20,230,453.1 | 35,803,178.04 | 96,990,497.44 | 178,682,557.44 |
| 九、综合收益总额 | 357,392,980.79 | 240,716,086.47 | 747,286,710.57 | 711,273,640.24 |
| 归属于母公司股东的综合收益总额 | 354,698,426.29 | 235,395,859.04 | 728,924,206.44 | 688,657,036.24 |
| 归属于少数股东的综合收益总额 | 2,694,554.5 | 5,320,227.43 | 18,362,504.13 | 22,616,604 |
| 公告日期 | 2026-08-28 | 2026-04-27 | 2026-04-27 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |